09 February 2020 2 Min Read
Demands for action on Remedica sale
Ascendis has had a tough run over the past four years, with its share price plunging more than 96%, from R28 in September 2016 to the current R1
Subscribe to our website to read this article and support quality journalism.
If you’ve already subscribed, simply sign in.
Subscribe Sign In